Medium urgency
-Moderately severe
Autoimmune disease caused by antibodies that attack the thin layer just below the outer layer of skin, forming large, itchy blisters.
The triggering cause is generally unknown eventhough cases of a drug (Etanercept, Sulfasalazine, Furosemide, Peniciline) onset related to UV light phototherapy and radiotherapy have been described.
It is diagnosed by examination of the lesions, a skin biopsy and measuring circulating antibodies.
The goal of the treatment is to relieve the itching and it is achieved through corticosteroids, immunosuppressants and biological agents.
Symptoms usually subside in a few months, but sometimes treatment is needed for several years.
- B.S. Daniel, L. Borradori, R.P. Hall 3rd, D.F. Murrell. Evidence-based management of bullous pemphigoid. Dermatol Clin, 29 (2011), pp. 613-620.
- D.F. Mutasim. Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management. Drugs Aging, 1 (2010), pp. 1-19.
- G. Di Zenzo, G. Marazza, L. Borradori. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol, 23 (2007), pp. 257-288.
- G. Kirtschig, N.P. Khumalo. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol, 5 (2004), pp. 319-326.
- S.M. Langan, L. Smeeth, R. Hubbard, K.M. Fleming, C.J. Smith, J. West. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.
- BMJ, 337 (2008), pp. a180.
- P. Joly, S. Baricault, A. Sparsa, P. Bernard, C. Bédane, S. Duvert-Lehembre, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol, 132 (2012), pp. 1
Dr. Abel Andrés Orelogio
Copyright© TeckelMedical 2026
